Drains vs no drains breast augmentation evidence addresses a deceptively simple question: after an implant is placed, should fluid be collected through a temporary closed-suction drain or should the pocket be left without one? In primary cosmetic augmentation, a drain is not automatically required by the implant itself. It is a surgeon-selected measure intended to remove blood or serous fluid while the early pocket is healing. Whether it adds benefit depends on the operation, the amount of dissection and bleeding, the tissue plane, the patient’s risk profile and the rest of the team’s protocol.
This review of drains vs no drains breast augmentation evidence focuses on primary cosmetic implant augmentation. It explains how the practice developed, what the direct comparative studies found, and why reconstruction or breast-reduction evidence cannot simply be substituted for an uncomplicated augmentation. The most useful conclusion is not “always drain” or “never drain”: it is that careful haemostasis and postoperative assessment remain essential whether a drain is used or not.
What is a surgical drain, and what is it meant to do?
A postoperative breast drain is usually a soft perforated tube connected to a closed, low-pressure suction reservoir. The tube sits in or near the implant pocket and exits through a separate small skin opening. The reservoir is emptied and measured, then the drain is removed when the surgical team considers the output and wound assessment appropriate. A drain is therefore a temporary route for fluid; it is not a device that seals blood vessels, sterilises a pocket, fixes implant position or prevents a capsule from forming.
Surgeons have traditionally used drains when they believe a newly created space could collect blood or serous fluid. A collection may cause swelling, pressure, pain or asymmetry, and a sizeable haematoma can require urgent assessment and sometimes return to theatre. Seroma is a different collection: it is predominantly clear inflammatory fluid rather than active bleeding. Both matter around an implant, but the presence of a drain does not guarantee that either will be prevented. A drain can remove fluid that reaches its holes; it cannot reliably evacuate a clotted haematoma, stop ongoing bleeding, or reach every compartment of a complex pocket.
Modern augmentation practice has increasingly emphasised gentle dissection, direct control of bleeding, careful pocket dimensions and structured follow-up. As those practices became more consistent, routine drains in straightforward primary cases became less common in many units. That change should not be mistaken for proof that drains are harmful in every situation. It reflects a balance between a possible benefit that has been difficult to demonstrate and real burdens such as discomfort, an exit wound, monitoring requirements and a potential route for bacterial entry.
Why an implant pocket raises the question
Creating an implant pocket separates tissue layers and produces a potential space. The pocket may be subglandular, subfascial, subpectoral or dual plane; each has different tissue relationships and dissection demands. The amount of oozing can also differ with anatomy, revision of a previous pocket, incision choice, medication exposure and surgical complexity. An implant does not eliminate that potential space. In fact, early fluid around an implant may be clinically important because it can distort the breast, complicate wound healing or prompt investigation for infection or another cause.
That logic explains why a surgeon may select a drain when the case has more than routine fluid risk. Examples can include an unexpectedly extensive dissection, difficult haemostasis, selected revision surgery, a large dead space, or a finding that changes the original plan. These are clinical judgments, not a menu that patients can use to self-select a technique. A planned cosmetic augmentation and immediate implant-based reconstruction after mastectomy are particularly different questions: reconstruction may involve larger raw surfaces, lymphatic disruption, cancer treatment, radiotherapy, an acellular dermal matrix or an expander. Its drain practice is informative background, not direct evidence for a healthy primary augmentation patient.
What direct augmentation studies have found
The 2020–2021 multicentre randomized trial
The most directly relevant study is Charles-de-Sá and colleagues’ prospective multicentre randomized comparative trial, published in 2021. It enrolled 150 women undergoing primary augmentation with 300 implants placed in a subglandular pocket. Participants were allocated to closed-suction drainage or no drainage. The drain group had measurements at 24 and 48 hours, while both groups had clinical review and ultrasound on day 7 and at three months, plus later follow-up intended to detect complications.
The drain group collected a substantial volume over 48 hours: the reported mean total was about 120 mL, with wide individual variation. That finding demonstrates that fluid can be removed; it does not, by itself, demonstrate that the same fluid would have caused a clinically important problem without drainage. On the ultrasound assessments, the investigators reported no statistically significant difference between the drained and undrained groups. Their conclusion was that closed-suction drainage added cost and time without a demonstrated recent postoperative benefit in this defined subglandular primary-augmentation cohort.
This is stronger evidence than a purely retrospective comparison because allocation was prospective and randomized. It is still not a final answer for every operation. The study’s surgical plane, patient population, local protocol, endpoints and sample size matter. A trial that finds no difference in early ultrasound fluid does not prove that every uncommon complication is identical, and it does not establish what should happen in revision surgery, reconstructive surgery or a case with unusual bleeding. It does, however, directly challenge the assumption that a drain is routinely necessary after every straightforward subglandular augmentation.
The dual-plane comparative study
A 2020 comparative study from a single hospital evaluated 123 patients undergoing dual-plane augmentation, with 57 patients in a drainage group and 66 without drainage. It reported no complications in either group and no meaningful group difference in operative time or the one-year BREAST-Q domains assessed. The undrained group had a shorter postoperative stay and lower hospital expense in that setting. The authors concluded that drainage may not be necessary for selected dual-plane augmentation patients.
The absence of complications makes the result reassuring but also limits what the study can prove. When a study has no haematomas, seromas or infections in either group, it cannot estimate a small difference in those events. The cohort was modest, its protocol may not resemble another surgeon’s, and published patient-reported outcomes cannot show that the groups would have the same results in a more complex population. Still, it adds to the direct literature by showing that an undrained pathway can be implemented in a selected dual-plane cohort without an obvious short-term penalty.
Systematic review: why the question remains unsettled
A 2022 systematic review searched for clinical studies of drains in primary breast augmentation that reported seroma, haematoma or infection. From 2,596 initially identified records, 38 articles met the broader inclusion criteria; 16 described drain use and 22 did not. Yet only five studies specifically investigated the effectiveness of drains in augmentation. Across the available literature, early complication rates appeared similar, but the authors could not determine whether drains changed seroma, haematoma or infection because the studies were heterogeneous.
Heterogeneity is not an academic technicality. Studies varied in implant plane, incision, drain type, removal threshold, surgeon experience, definitions of seroma and haematoma, use of compression or antibiotics, and duration of follow-up. Some compared different eras of a surgeon’s practice, so a change in drains may have occurred alongside changes in devices, pocket technique or haemostasis. For those reasons, the systematic review called for additional randomized trials rather than declaring a universal standard. Its conclusion is compatible with a selective approach: current evidence does not establish routine drain use as superior in primary augmentation, but it also does not prove that no-drain practice is correct for every clinical circumstance.
How a no-drain series should be interpreted
In 2023, Montemurro and Gupta reported a single-surgeon series of primary breast augmentations performed without drains. Of 1,617 patients with at least six months of follow-up, they reported haematoma in 0.92%, seroma in 0.74%, explantation for infection in 0.18% and capsular contracture in 2.72%. These figures show that a no-drain protocol can coexist with relatively low reported complication rates in an experienced practice.
However, a consecutive case series does not test the causal effect of omitting drains. There was no concurrently drained comparison group, 429 patients were lost to follow-up before the analysis, and reported rates depend on definitions and duration of surveillance. The publication argues against unwarranted routine drainage, but it cannot establish that drains would have increased infection, pain or any other outcome in its own patients. The most defensible use of this study is as real-world feasibility evidence, not as a promise that no-drain surgery has a particular complication rate.
Drains, haematoma and the importance of haemostasis
It is tempting to think that a drain prevents a haematoma. A better way to frame the issue is that prevention begins before closure: identifying and controlling bleeding, checking the pocket under appropriate blood pressure conditions, avoiding unnecessary tissue trauma and responding to individual bleeding risks. A closed-suction drain may reveal bloody output or remove some non-clotted blood, but it does not make active bleeding safe. A rapidly enlarging breast, increasing one-sided pain, tightness, marked asymmetry, dizziness, fever, wound change or concerning drainage requires prompt clinical assessment rather than reassurance from the existence of a tube.
The wider augmentation literature also shows that complication rates can vary by pocket plane, patient selection and study design. A 2024 systematic review and meta-analysis comparing subfascial with subglandular placement found lower pooled haematoma rates in the subfascial group, but every included study had high risk of bias. This does not direct drain use in an individual patient. It does illustrate why a drain-only comparison can be misleading when the plane, dissection and anatomy may be more influential than the drainage decision.
For a deeper review of pocket variables, see the evidence on breast implant pocket placement. The related haemostasis and haematoma-prevention review explains why a drain is not a substitute for meticulous operative bleeding control.
Potential disadvantages of drains
Drains are not neutral simply because they are familiar. They can create local discomfort and anxiety, require a patient or carer to manage a reservoir, and leave a small exit wound after removal. A drain can become blocked, kinked or accidentally dislodged. It can also lead to different antibiotic practices, although antibiotic duration should be determined by the surgeon’s evidence-based protocol rather than by a patient’s assumption that a drain itself requires prolonged medication.
Infection is often discussed as a theoretical concern because the drain connects the pocket to the outside environment. That pathway is plausible, but primary augmentation studies have not established a reliable, universal increase or decrease in infection caused by a drain. The appropriate statement is more modest: the exit site must be managed carefully, and the possible infection burden belongs in a balanced discussion. The same restraint applies to pain. Some studies and clinical experience indicate that drains can be uncomfortable; they do not prove that every person will find a drain intolerable or that no-drain surgery will be painless.
Why reconstruction evidence cannot decide cosmetic augmentation practice
Implant-based reconstruction papers often evaluate drains because mastectomy creates a larger and biologically different wound than cosmetic pocket creation. A 2007 cohort study of tissue-expander exchange to permanent implants found no difference in perioperative infection, seroma or haematoma between procedures with and without periprosthetic closed-suction drains. That is useful confirmation that drains are not automatically protective even in a reconstructive exchange setting. It is not a basis for directly calculating risk after elective augmentation.
Immediate reconstruction patients may have cancer-related treatment, radiotherapy, mastectomy skin-flap concerns, lymphatic changes, expanders or support matrices. They may also have different reasons for admission and different thresholds for fluid aspiration or reoperation. Those differences can make a drain more or less relevant than in aesthetic practice. Separating populations is an important safeguard against a common online error: presenting a reconstruction complication rate as if it were an estimate for cosmetic augmentation.
What a patient can reasonably ask in consultation
Rather than treating a drain as a quality badge, a patient can ask whether the surgeon normally uses drains for the proposed operation and what would make the plan change during surgery. Helpful questions include: What pocket is planned? What steps are used to control bleeding? How would a haematoma or seroma be assessed if I do not have a drain? If a drain is used, where will it exit, how will I record output, when is removal considered and whom do I contact for a concern? These questions invite an explanation of a protocol, not a guarantee.
Procedure context is available on the breast augmentation operation and planning page. Readers comparing several intra-operative measures can also review breast implant pocket irrigation evidence and the no-touch and Keller Funnel evidence review. Each describes a separate possible intervention; none should be treated as a guarantee against infection, contracture, bleeding or revision.
Limitations of the current evidence
The direct evidence base is small. Even the best augmentation trial studied a defined subglandular population, and rare events need far larger samples to compare confidently. Many reports are observational, and a surgeon who chooses to use a drain may be dealing with a more complex case. This is called confounding by indication: the reason for a drain may also be the reason a patient has a higher baseline risk. Conversely, an experienced no-drain practice may select patients or apply meticulous techniques that do not transfer automatically to every setting.
Outcome definitions are also inconsistent. An ultrasound-detected fluid collection, a symptomatic seroma requiring aspiration and a return to theatre are different endpoints. Studies can measure them at different times and still call them “seroma.” Follow-up loss matters especially for later outcomes such as capsular contracture, which has a multifactorial biology and should not be attributed to drainage based on short-term data. Future trials should report a transparent drain-removal protocol, operative plane, implant characteristics, fluid and bleeding definitions, patient-reported burden, infection criteria and longer follow-up.
Conclusion
Current drains vs no drains breast augmentation evidence does not support routine closed-suction drainage as a proven way to prevent seroma, haematoma or infection after every primary cosmetic implant operation. A multicentre randomized trial in subglandular augmentation found no recent postoperative benefit, and a systematic review found that heterogeneity prevented a firm conclusion about early complications. Selected dual-plane and no-drain series also show that no-drain protocols can be feasible when the surgical team uses careful haemostasis and follow-up.
That does not make drainage an error in every case. A drain may be a reasonable response to a specific intra-operative finding or a more complex procedure. The informed choice is procedure-specific and should be explained by the operating surgeon as part of an overall safety protocol. The evidence supports proportionate language: a drain can remove fluid, but it cannot replace bleeding control or guarantee a complication-free recovery.
Frequently asked questions
Are drains routinely needed after breast augmentation?
No universal rule applies. Direct studies in selected primary augmentation cohorts have not shown a clear routine benefit, but a surgeon may choose a drain when the procedure or intra-operative findings create a different fluid or bleeding concern.
Can a drain prevent a haematoma?
Not reliably. A drain may remove some fluid, but it cannot stop bleeding or reliably evacuate a clotted collection. Meticulous haemostasis and prompt assessment of new swelling or asymmetry are more fundamental safeguards.
Does no-drain breast augmentation increase infection risk?
The available augmentation evidence does not demonstrate a consistent increase. It is also not strong enough to promise that no-drain surgery lowers infection risk for every patient. Infection prevention depends on the entire sterile and postoperative protocol.
Are reconstruction drain studies the same as augmentation drain studies?
No. Reconstruction can involve mastectomy, cancer treatment, radiotherapy, tissue expanders and support materials. Those factors alter healing and fluid risk, so reconstruction results should not be used as a direct prediction for primary cosmetic augmentation.
What symptoms should prompt urgent contact after surgery?
Rapidly increasing one-sided swelling, severe or escalating pain, marked asymmetry, faintness, fever, wound changes, foul drainage or a drain that stops or dislodges should be assessed promptly using the surgeon’s postoperative contact instructions. This article cannot assess an individual complication.
If I have a drain, when will it be removed?
Removal timing varies by operative finding, output pattern and the surgeon’s protocol. A number from another patient or website is not a safe personal threshold. Ask the surgical team how output will be recorded and what their removal criteria are.
Sources and references
- Charles-de-Sá et al. Drainage on augmentation mammoplasty: Does it work? Journal of Plastic, Reconstructive & Aesthetic Surgery, 2021. Prospective multicentre randomized comparison of closed-suction drainage and no drainage in subglandular primary augmentation.
- A Shakespearean Dilemma in Breast Augmentation: to Use Drains or not? A Systematic Review Aesthetic Plastic Surgery, 2022. PRISMA systematic review; study heterogeneity prevented a firm conclusion about early complications.
- To use indwelling drainage or not in dual-plane breast augmentation mammoplasty patients: A comparative study, 2020. Comparative dual-plane cohort with one-year BREAST-Q assessment.
- Montemurro and Gupta. It Is Time to Resolve the Dilemma and Move Away From Using Drains in Primary Breast Augmentation Aesthetic Surgery Journal Open Forum, 2023. Single-surgeon no-drain series; observational feasibility evidence rather than a causal comparison.
- Yuan et al. Outcomes in Subfascial Versus Subglandular Planes in Breast Augmentation Aesthetic Surgery Journal, 2024. Systematic review and meta-analysis; high risk of bias in included studies.
- McCarthy et al. The effect of closed-suction drains after tissue expander/implant reconstruction Plastic and Reconstructive Surgery, 2007. Reconstruction cohort included to illustrate population limits, not as direct augmentation evidence.
- Horsnell, Searle and Harris. Intra-operative techniques to reduce the risk of capsular contracture Surgeon, 2017. Review of intra-operative measures and evidence limitations.
- ERAS Society breast-surgery resources. Broader perioperative guidance; not a cosmetic augmentation drain directive.
Author and medical-review metadata
Author: BreastAugmentationInTurkey.org Editorial Team
Medical reviewer: Independent qualified plastic and reconstructive surgeon — medical reviewer to be confirmed before publication
Published: 11 September 2026
Evidence updated: 11 September 2026
Scope: Educational review of primary cosmetic breast augmentation; reconstructive evidence is identified separately and is not assumed to transfer directly.
Editorial limitation: This article does not diagnose a postoperative collection or recommend an individual drain plan. It should be updated if a sufficiently powered trial or authoritative guideline materially changes the evidence.